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Background. An in vitro basophil activation test, based on the detection of CD63 upregulation induced by NSAIDs, has
been described. Its clinical signiﬁcance remains controversial. Objectives. In patients with a history of nonallergic NSAID
hypersensitivity, stratiﬁed according to the severity of the symptoms, to assess with NSAIDs the predictive value of basophil
(BAT) and monocyte (MAT) activation tests. Patients/Methods. Sixty patients who had NSAIDs-induced or exacerbated
urticaria/angiooedema and 20 controls was included. After incubation with NSAIDs or acetaminophen, leukocytes were analysed
for CD63 upregulation. Results. With aspirin, the sensitivity (37%) and speciﬁcity (90%) of BAT agree with already published
results. In contrast, when patients had had cutaneous and visceral reactions, the frequency of positive BAT 14/22 (64%, P<0.001)
or MAT 10/22 (46%, P<0.01) were increased. Conclusions. Positive tests were more frequent among patients having a severe
hypersensitivity contrasting with the other patients who had results similar to controls.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are after
antibiotics, the second most frequently suspected agents
causing drug hypersensitivity. The prevalence of acetyl sal-
icylic acid (ASA, aspirin) hypersensitivity ranges from 0.6%
to 2.5% in the general population, from 4.3% to 11% in
asthmatic patients [1], and from 20 to 40% in chronic idio-
pathic urticaria (CIU) [2]. It also occurs in subjects with no
known underlying disease, otherwise normal when they ab-
stain from taking NSAID.
Hypersensitivity may occur shortly, within 15 minutes
or longer, up to 24 hours after NSAID intake. In general
it develops within 1 to 4 hours [3]. Some patients might
have life-threatening reactions, especially those with aspirin-
exacerbated respiratory diseases (AERDs, Widal syndrome),
which associate aspirin sensitivity, asthma, nasal polyposis,
and airway remodelling [1].
In most patients the adverse reaction is nonallergic.
Those with eicosanoid metabolism dysfunction or other
alterations are prone to hypersensitivity when NSAIDs
inhibit the enzyme cylooxygenase-1 (Cox-1) [3–14]. Selec-
tive NSAIDs strongly inhibit COX-2, but they are weak
inhibitors of COX-1, so they are well tolerated in patients
with NSAID-sensitive asthma or CIU [4, 5]. The concen-
tration inhibiting eﬃciently COX-1 or COX-2 may diﬀer
as much as 3 logs between the strongest and weakest
inhibitors (Table1)[15–17].Pharmacologicalproﬁlesaswell
as hypersensitivity depend on their inhibitory activities.
The diagnosis of NSAID hypersensitivity is based on
clinical histories and provocation challenges with aspirin
or NSAIDs [19–21]. Skin test (ST) responses are typically
negative except when there is a true allergy. Oral challenge
tests rule out hypersensitivity in 50% of the patients [20]
which suggests that clinical histories are not suﬃcient to
diagnose true NSAID hypersensitivity. Due to the severe2 Journal of Allergy
Table 1:ComparisonofNSAIDsandacetaminophenconcentrationsincubatedwithleukocytestoserumconcentrationsatusualtherapeutic
dosage and to 50% inhibitory concentrations (IC50) of cyclooxygenase-1 and -2.
Drug
Concentrations
Tested∗ In serum∗∗ IC50∗∗∗
mg/mL μM μM COX-1 COX-2
ASA 0.01–0.1–1 31–310–3100 111 4.45 13.88
Diclofenac 0.0013–0.013–0.13 4.2–42.2–422 6.1 0.26 0.01
Ketoprofen 0.025–0.25–2.5 98.3–983–9830 9.4 0.11 0.88
Celecoxib 0.005–0.05–0.5 13.1–131–1310 1.6 82 6.8
Acetaminophen 0.01–0.1–1 66.1–661–6610 117 113.7 25.8
∗Each NSAID and and acetaminophen (APAP) were tested at three ten-fold serial dilutions.
∗∗Serum concentrations at usual therapeutic dosage.
∗∗∗Concentration of drug that inhibited 50% of COX-1 in platelets or COX-2 in monocytes [15–17].
reactions that might occur in some patients, it was not
desirable to use oral challenge systematically. There is a need
for laboratory tests; hence ﬂow cytometric determination
of CD63 upregulation on basophils incubated with aspirin
and other NSAIDs has been described. Sensitivity has been
shown to be 43% with aspirin or diclofenac [7, 22, 23].
However, conﬂicting results have also been published about
the speciﬁcity or the sensitivity of the test and the clinical
signiﬁcance [21, 24–26].
In ASA-induced urticaria or asthma, in addition to
basophils, neutrophils or other leukocytes are also activated
[8, 27]. The aim of the present study is in patients
suﬀering from nonallergic NSAID hypersensitivity, stratiﬁed
according to the severity of clinical symptoms, to compare
theclinicalperformanceofthebasophilactivationtest(BAT)
with the monocyte (MAT) activation test.
2. Patientsand Methods
2.1. Patients. Sixty-ﬁve patients referred by the patients’
physician or by an emergency unit to the Dermatology
and Allergy Center of Hˆ opital Tenon, Paris, between 2006
and 2009 for evaluation of a history of NSAID and/or
APAP (acetaminophen, paracetamol) hypersensitivity were
included in the study. Among them, 5 patients had APAP
hypersensitivity alone. Half of patients according to the
physician report or the patient’s declaration had a history of
hypersensitivity to one of these drugs during the last year, for
the other half it was older.
NSAID-induced or exacerbated urticaria or angiooede-
ma and associated symptoms were clinically classiﬁed [21,
28,29],andseverityofclinicalsymptomswasgradedaccord-
ing to the published works [18]. Hypotension was deﬁned
as a systolic blood pressure below 100mm. Patients with
recurrent angiooedema were investigated for complement
fractions C3 and C4 and C1 inhibitor, but their results were
in normal ranges.
Patients suspected of immediate or delayed allergy to
an NSAID were discarded. Those with asthma or Widal
syndrome were not included because they were followed up
in the department of respiratory system diseases.
The study protocol was in accordance with the local
ethical committee guidelines, and all subjects gave their
consent before being included. Tests were done only for a
diagnostic purpose.
2.2. Controls. Leukocytes from 12 normal subjects, members
of the hospital’s staﬀ, and 8 patients with allergic reactions
induced by drugs other than NSAIDs were used as controls
for BAT, MAT, and NAT. All the controls had never experi-
e n c e dN S A I Dh yp e r s e n s i t i vi tya n dh a dt a k e na tl e a s to n c e1g
aspirin within the last 12 months.
2.3. Skin Tests. Skin tests (STs), prick ST and intradermal ST,
were done as previously described [30, 31].
2.4. Oral Challenge Test. In this study no oral challenge test
with NSAIDs was done for a diagnostic purpose. In patients
needingananalgesicantipyreticdrug,doubleblind,placebo-
controlled, orally given APAP tests were carried out when
the STs were negative. Protocol for patients needing NSAID
therapy was similar, they received selective NSAIDs celecoxib
or nimesulide. All the oral challenges were done by the same
practitioner.
2.5. NSAIDs for Flow Cytometry. They were purchased in
solution for intravenous or intramuscular use. Acetyl salicy-
late lysine (Aspegic, Sanoﬁ-Aventis), acetaminophen (APAP,
paracetamol, perfalgan, Bristol-Myers Squibb), ketoprofen
(profenid, Sanoﬁ-Aventis), diclofenac (voltaren, Novartis
Pharma) and celecoxib (Celebrex, Pﬁzer Inc.) were diluted
in the dilution buﬀer (2mM MgCl2,1 . 2 m MC a C l 2,a n d
2g/L bovine serum albumin in phosphate-buﬀered saline,
PBS). The dilution buﬀer was used, instead of a NSAID, as
the negative control in two tubes, and calcium ionophore
2.5μg/mL (Sigma) was used as the positive control. Calcium
ionophore induced CD63 upregulation in at least 50% of
basophils and monocytes and 25% of neutrophils.
2.6. Antibodies. R-phycoerythrin-conjugated anti-CD33
monoclonal antibody (MAB), ﬂuorescein-isothiocya nate-
(FITC-) conjugated anti-CD63 MAB, R-phycoerythrin-con-
jugated anti-CD203c MAB, tandem dye R-phycoerythrin-
cyanin-5.1-conjugated anti-CD45 MAB, and ECD-conjugat-
ed (tandem dye phycoerythrin-Texas red) strep- tavidin were
purchased from Beckman Coulter- Immunotech, Marseille,Journal of Allergy 3
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Figure 1: Detection by ﬂow cytometry of CD63 upregulation on leukocytes activated by NSAIDs. (a) and (b) Targeting of leukocytes:
(a) shows at the top CD33 bright cells, the monocytes, CD33 dim cells, polymorphonuclears, and CD33-negative cells, lymphocytes. (b)
Shows among anti-IgE-labelled cells, CD33dim cells, the basophils, and C33 bright, the monocytes. The percentage of monocytes among
IgE-labelled cells varies from 0 to 50%, depending on the patient. (c) and (d) Activation of basophils: (c) basophils incubated with buﬀer.
(d) Basophils incubated with 1mg/mL of ASA and upregulation of CD63 on 30% of basophils. (e) and (f) Activation of monocytes and
neutrophils.(e)Monocytesatthetop,andneutrophilsunder,incubatedwithbuﬀer.(f)Afterincubationwith1mg/mLofASA,upregulation
of CD63 on 25% of monocytes and 5% of neutrophils.4 Journal of Allergy
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Figure 2: ROC curves for basophils and monocytes incubated with 1mg/mL of ASA. (a) shows the sensitivity (Se) and the speciﬁcity (Sp)
of BAT. The cut-oﬀ value was determined at 6% of activated basophils (vertical dashed line). (b) shows ROC curves for the activation of
basophils and monocytes. The diagnostic performance of the activation of basophils was better (area under the curve for activated basophils
0.855) than that of the activation of monocytes (area under the curve 0.718), P<0.001.
France. Biotinylated goat anti-human IgE polyclonal anti-
body was purchased from Vector Laboratories, Burlingame.
2.7. Leukocyte Activation Tests. The BASIC (basophils iso-
lated from blood and analysed by ﬂow cytometry) assay
was done as previously described [30, 31]. Lithium-heparin
anticoagulated peripheral blood was centrifuged at 500g for
20 minutes at 20◦Co nal a y e ro fﬁ c o l l( d = 1.077). The
lymphocyte layer and leukocytes suspended in ﬁcoll between
lymphocytes and red cells were harvested. After lymphocytes
the largest population among these cells were neutrophils,
then monocytes, and basophils were the smallest one.
100μL aliquots of the leukocyte suspension containing
106 leukocytes were mixed with 100μL of antigen or dilution
buﬀer and then incubated for 30min at 37◦Ci naC O 2 (7%)
incubator, after which the cells suspensions were ﬁxed by the
addition of 50μL of 1% paraformaldehyde in PBS.
The leukocytes were then quadruple labelled by adding
10μL FITC-conjugated anti-CD63 antibody, 20μL R-phyco-
erythrin-conjugated anti-CD33 antibody 10μLt a n d e m
dyeR-phycoerythrin-cyanin-5.1-conjugatedanti-CD45anti-
body, and 1/50 diluted 50μL biotinylated anti-IgE antibody.
For the analysis of the CD203c upregulation, basophils were
quadruple labelled using the same antibodies, except that the
anti-CD33 antibody was replaced by 20μL R-phycoerythrin-
conjugated anti-CD203c. After incubation and washing
biotinylated anti-IgE antibodies were labelled by adding
10μL ECD-conjugated (tandem dye phycoerythrin-Texas
red) streptavidin.
Analysis of leukocytes surface markers was performed on
an Epics XL ﬂow cytometer (Beckman Coulter, Marseille,
France). On the histogram deﬁned by forward scatter and
side scatter, the ﬁrst gating was done by a bit map around
lymphocytes and monocytes, basophils were found in this
gate. Another gate was done around polymorphonuclear
leukocytes, for neutrophils. The next gatings were done for
basophils around IgE+ CD45+ CD33dim cells (Figure 1).
These cells previously had been identiﬁed as basophils [31–
33]. Monocytes were gated around CD45 bright and CD33
bright cells[33], a small proportion of them being IgE+ [31].
The second gating for neutrophils was done around CD45+
CD33dim IgE− cells (Figure 1). When CD203c, a speciﬁc
marker of basophils [34, 35] was used, basophils were gated
around CD203c+ IgE+ CD45+ cells.
In each assay, upregulation of CD63 was measured on at
least 400 cells for basophils, monocytes, or neutrophils.
2.8. Cut-Oﬀ for Positive Results. The tube-to-tube repro-
ducibility was determined by labelling leukocytes of 10
patients and counting 12 tubes per patient. A cut-oﬀ value
for positive results was chosen at 2 standard deviations (6%)
exceeding the value of the nonstimulated control tube.
The best cut-oﬀ value for activated basophils and mono-
cytes was established by analysing the receiver operating
characteristic (ROC) curves of results observed in a selected
group of patients with severe hypersensitivity versus controls
(Figure 2). The optimal cut-oﬀ point deduced from ROC
curves was approximately 6% of activated cells. It was similar
tothatcalculatedintube-to-tubereproducibility(seeabove).
2.9. Statistical Analysis. Results of BAT and MAT were blind-
analysed, the operator was not informed of the patients’
diagnosis. Conversely, the diagnosis of allergy was done
before the results of BAT and MAT were available. Statistical
analysis was done with χ2,p a i r e dχ2, a two-tailed Fisher’s
test, Wilcoxon’s nonparametric test, and Spearman’s rank
correlation.
3. Results
3.1. Clinical History and Classiﬁcation of Patients with
NSAID Hypersensitivity. Among 60 patients with NSAID
hypersensitivity, 30 had no underlying disease and had
recovered when they abstained from taking NSAIDs. These
patients were diagnosed as having NSAIDs-induced urti-
caria/angioedema according to [21]. The most frequent andJournal of Allergy 5
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Figure 3: Activation of patients’ and controls’ basophils and monocytes incubated with 1mg/mL of ASA. (a) Basophils, (b) monocytes.
Grading of reactions in the NSAID hypersensitivity was done according to severity of clinical symptoms [18]( T a b l e3). The median value is
shown by the horizontal bold lines. The cut-oﬀ for a positive BAT or MAT was determined at 6% of activated cells (dashed line). Statistical
analysis was performed by Wilcoxon’s nonparametric test.
Table 2: Description of patients suﬀering from NSAID hypersensitivity.
Group of patients∗ Age Sex ratio Atopy∗∗ C/E IU∗∗∗ HS ≥ 2∗∗∗∗ NSAIDs
Grade I n = 38 44 29F/9M 9 (24%) 18 (47%) 25 (66%)
Grade II n = 22 43 16F/6M 7 (32%) 12 (55%) 17 (77%)
Total n = 60 44 45F/15M 16 (27%) 30 (50%) 42 (70%)
∗Patients with a history of urticaria or angiooedema and no visceral disorder were classiﬁed as having had a hypersensitivity of grade I and those with atl e a s t
one visceral disorder were classiﬁed as grade II according to published works [18].
∗∗Patients had history of atopic dermatitis, allergic rhinitis, or asthma, but they had healed at the time of NSAID hypersensitivity.
∗∗∗The patients with “C/E IU” had chronic or episodic idiopathic urticaria or angiooedema; NSAID hypersensitivity was diagnosed when symptoms worsen
relapsed, or were unusual and recovered when they stopped NSAID intake.
∗∗∗∗Patients who had histories of hypersensitivity induced by at least two chemically distinct NSAIDs.
characteristic clinical manifestation of the NSAID hypersen-
sitivitywasfacialangiooedema withoutﬂares,observedin20
patients (67%) (P>0.01).
The remaining 30 patients had chronic and/or episodic
(intermittent) idiopathic urticaria and/or angiooedema (C/E
IU). NSAID-induced angiooedema was as frequent as ur-
ticaria. These patients were diagnosed as having NSAIDs-
exacerbated urticaria/angioedema according to [21]. The
demography of patients is described in Tables 2 and 3.
Forty-two among 60 patients (70%) had histories of
hypersensitivity induced by at least two chemically distinct
NSAIDs (Table 2). For the remaining 18 patients we cannot
settle if they were true single- or multiple-NSAID reactors
because they abstained from taking NSAIDs after the ﬁrst
hypersensitivity reaction. Twenty patients (33%) had also
a clinical history of APAP hypersensitivity associated with
NSAID hypersensitivity (not shown). All patients with APAP
hypersensitivity had a negative ST to APAP. Out of 20
patients with clinical history of APAP and NSAID hypersen-
sitivity and 5 patients with only APAP hypersensitivity, re-
spectively,5 (25%) and 1 (20%) had APAPoral challengetest
positive.
Twenty-two patients with a history of urticaria or an-
giooedema and with at least one visceral disorder hypoten-
sion, laryngeal oedema, dyspnoea, abdominal pain, vomiting
or diarrhoea after NSAID intake, were classiﬁed as having
had a hypersensitivity of grade II (Table 4). After NSAID
intake, 21 reacted before 6h (21/22 = 95%, median 1h).
In contrast, in patients with a history of urticaria or an-
giooedema with no visceral involvement (grade I), hypersen-
sitivity occurred later (median 8h) (P<0.0001) (Table 3).
Among 18 patients with only one known NSAID hyper-
sensitivity, 7 had at least one visceral disorder, frequency
(7/18) was similar to patients with hypersensitivity induced
by at least two chemically distinct NSAIDs (15/42). No
clinical or biological data could discriminate one group from
the other.
3.2. Tests for the Detection of In Vitro Activated Leukocytes
by NSAIDs. Targeting of leukocytes and detection of CD63
upregulation on the membrane of activated cells were done
as indicated in Figure 1. A cut-oﬀ value for positive results
was chosen at 2 standard deviations (in tube-to-tube repro-
ducibility), 6% exceeding the value of the nonstimulated
c o n t r o lt u b e( s e eS e c t i o n2 for more details). This value
was similar to the optimal cut-oﬀ point deduced from ROC
curvesforthebasophilactivationtest(BAT)orthemonocyte
activation test (MAT) (Figure 2).
3.3. CD63 Upregulation Induced by ASA
3.3.1. On Basophils. Twenty-two out of 60 patients with a
history of NSAID hypersensitivity had a positive BAT to ASA
at 1mg/mL; therefore the sensitivity was 37%. Two controls
among 20 (10%) had positive BAT to ASA, the speciﬁcity of
the test could be estimated close to 90%.6 Journal of Allergy
Table 3: Skin symptoms and time to onset of the NSAID-induced hypersensitivity.
Group of patients Time to onset∗ NSAID-induced skin symptoms
Median <6H AO AO + Urticaria Urticaria
Grade I n = 38 8H 14 (37%) 18 (47%) 9 (24%) 11 (29%)
Grade II n = 22 1H 21 (95%) 12 (55%) 7 (32%) 3 (14%)
Total n = 60 4.5H 35 (58%) 30 (50%) 16 (27%) 14 (23%)
∗The time to onset of symptoms after NSAID intake was shorter in patients with grade II hypersensitivity than in patients with grade I (P<0.0001).
Table 4: Description of severe reactions (grade II) observed in patients with NSAID hypersensitivity.
Grade II reactions/time to onset∗ Visceral disorders (VD)
Laryngeal oedema Dyspnoea∗∗ Hypotension G-intestinal disorders At least one VD∗∗∗
<6H n = 21 9 (43%) 8 (38%) 6 (29%) 3 (14%) 21 (100%)
8H n = 11 0 0 0 1
Total n = 22 10 (45%) 8 (37%) 6 (27%) 3 (14%) 22 (100%)
∗Time to onset of symptoms after NSAID intake. ∗∗Dyspnoea observed in patients with no laryngeal oedema. ∗∗∗Patients with a history of urticaria or
angiooedema and with at least one visceral disorder were classiﬁed as having had a hypersensitivity of grade II according to published works [18].
In patients suﬀering from NSAID hypersensitivity re-
stricted to cutaneous reaction (grade I), positive BAT to ASA
was not more frequent than in control group (Figure 3 and
Table 5).
In contrast, in patients who had had a grade II hyper-
sensitivity, basophils were more strongly activated and BAT
was more frequently positive (14/22 = 64%) than in patients
with grade I (8/38 = 21%) or controls (Figure 2 and Table 5)
(P<0.001, Wilcoxon’s nonparametric test). Therefore, a
positive BAT in a patient with NSAID hypersensitivity had
for a grade II hypersensitivity a positive predictive value of
64% (14/22). The negative predictive value was 79%; only 8
out of 38 patients with a negative BAT had had a grade II
hypersensitivity.
A positive BAT to ASA correlates with the precocity of
the hypersensitivity. The patients with a positive BAT had
reported an interval of 2.5 hours (median value) between
NSAID intake and symptoms. On the other hand among
patients with negative test the interval was 8 hours (P<
0.001).
3.3.2. On Monocytes and Neutrophils. Though less sensitive
(46%), results of MAT correlate quite well with BAT (Spear-
man’s rank correlation, r = 0.71 for ASA, r = 0.49 for
diclofenac, P<0.001). The mean percentage of activated
monocytes with ASA was greater in patients with grade
II hypersensitivity than in those with grade I (P<0.01)
or controls (P<0.02, Wilcoxon’s nonparametric test)
(Figure 2). In control group, in comparison with BAT, the
number of results exceeding the cut-oﬀ was increased and
not signiﬁcantly diﬀerent from that of patients. Therefore,
the speciﬁcity of MAT was relatively low, 75% (Table 5).
Activation of neutrophils with ASA was rather insigniﬁ-
cant (Table 4).
3.4. Results Observed with Other NSAIDs and APAP. Acti-
vation by diclofenac of basophils and monocytes was of
the same magnitude of ASA and results correlated rather
well (Spearman rank correlation, r = 0.59, P<0.01). In
contrast, it activated neutrophils better than ASA (Table 5,
P<0.01). The mean percentage of activated basophils
was greater in grade II patients (median 4.3, range 28–
0%) than in grade I patients (median 0.7, range 19–0%)
(P<0.03, Wilcoxon’s nonparametric test). However, the
number of values exceeding the cut-oﬀ w a sn o ts og r e a tt o
be signiﬁcant between grade II, grade I or controls (P =
NS) (Table 4). Ketoprofen, celecoxib, and APAP activated
basophils, monocytes, or neutrophils, with values exceeding
thecut-oﬀin10to16%ofpatientsandin0to5%ofcontrols
(results not shown). APAP did not activate signiﬁcantly cells
of patients with NSAID and APAP hypersensitivity (n = 20)
or APAP hypersensitivity alone (n = 5) (results not shown).
3.5. Optimal NSAID Concentrations Activating Leukocytes.
Each NSAID and APAP were tested at three ten-fold serial
dilutions (Table 1). For each drug the highest concentration
was calculated in relation with usual pharmacological doses
and tested on leukocytes in order to check the absence of
toxic eﬀects. For ASA and diclofenac, available solutions
for IV and IM use were at least diluted 1/200 to obtain a
ﬁnal concentration of 1mg/mL for ASA and 0.125mg/mL
for diclofenac. We avoided 1/20 diluted solutions because
they seemed toxic. The percentage of positive tests decreased
with increasing dilution; at 1/2000 they were two times less
frequent than at 1/200 (results not shown). Results shown
are those observed at the dilution 1/200 (Table 4). For
ketoprofen and APAP, as they seldom activate leukocytes,
available solutions were less diluted: 1/20, 1/200, and 1/2000
(ﬁnal concentration in Table 1). No toxic eﬀect had been
observed with these dilutions.
3.6. Comparison of Two Basophil Activation Markers, CD63
and CD203c. In 23 patients and 8 controls, basophils were
double labelled with the two activation markers. ActivationJournal of Allergy 7
Table 5: Activation of basophils (BAT), monocytes (MAT), and neutrophils (NAT) induced in vitro by ASA (1mg/mL) or diclofenac
(0.125mg/mL).
Patients with positive tests∗
Group of patients BAT+ MAT+ NAT+
ASA Diclofenac ASA Diclofenac ASA Diclofenac
NSAID HS n = 60 22 (37%) 20 (33%) 14 (23%) 15 (25%) 8 (13%) 16 (27%)
Grade I∗∗ n = 38 8 (21%) 10 (26%) 4 (11%) 9 (24%) 6 (16%) 12 (31%)
Grade II n = 22 14 (64%) 10 (46%) 10 (46%) 6 (27%) 2 (9%) 4 (19%)
Controls n = 20 2 (10%) 5 (25%) 5 (25%) 3 (15%) 0 (0%) 2 (10%)
∗The optimal cut-oﬀ point for a positive test deduced from ROC curves was 6% of activated cells (see Section 3). Activation was detected by CD63
upregulation. ∗∗Grading of reactions according to severity of clinical symptoms (Tables 2 and 4).
of patients’ basophils with ASA, diclofenac, or ketoprofen
was detected 32 times with CD63, 6 times with CD203c,
and 4 times with both CD63 and CD203c (results not
shown). CD63 was at least 5 times more sensitive than
CD203c (P<0.0001). In the control group, basophils
activation was detected 5 times with CD63 and 10 times with
CD203c. NSAIDs-induced upregulation of CD203c was not
signiﬁcantly diﬀerent between patients and control group.
4. Discussion
The sensitivity (37%) and speciﬁcity (90%) of BAT for the
diagnosisofNSAIDinducedhypersensitivitywerelow.These
values rather agree with published results. The sensitivity
of BAT was assessed between 33 and 77% with ASA and
between 17 and 52% with diclofenac [7, 22, 23, 26, 36–38].
Our cut-oﬀ for positive results, at 6% of activated basophils,
was slightly higher than the published values. In order to
improve the sensitivity of the test, instead of the results
observed with a single NSAID, those observed with ASA,
diclofenac, and naproxen were combined in an index (ADN
index) [26]. As a consequence the sensitivity increased from
43% to 65%.
Our study further shows that, though less frequent than
on the basophils, ASA upregulates CD63 on the monocytes
of some patients with NSAID hypersensitivity and of some
control subjects who tolerate ASA well. Because BAT and
MAT have a low sensitivity and speciﬁcity in the diagnosis
of NSAID hypersensitivity, this raises the question of the
clinical signiﬁcance of a positive test.
Our results suggest a linkage between positive BAT
or MAT with ASA and a history of a severe NSAID
hypersensitivity. Indeed positive tests were more frequent
in patients with severe hypersensitivity than in patients
with only cutaneous symptoms or controls (P<0.001).
Conversely, in patients with only cutaneous symptoms after
NSAID intake the frequency of positive BAT or MAT was
quite similar to that in controls. Because the patients with
NSAID hypersensitivity are heterogeneous, the conﬂicting
results could be explained by bias of selection [7, 22, 23, 26,
36–38].Stratiﬁcationofthepatientsaccordingtotheseverity
of the clinical symptoms has not been used in the appraisal
of the clinical signiﬁcance of a positive test.
The patients included in this study had been suspected of
a nonallergic hypersensitivity to NSAIDs. For most of them
this was conﬁrmed because 70% had histories of hypersensi-
tivitywithatleasttwochemicallydistinctNSAIDs;moreover,
in addition to basophils, monocytes were activated in vitro
by NSAIDs. Because activation of monocytes is not IgE
dependent, a positive MAT might contribute to identify a
nonallergic hypersensitivity. Among 18 patients with only
one known NSAID hypersensitivity, 7 patients were MAT
positive with ASA or diclofenac.
Results observed in BAT and MAT agree with clinical
studies about harmlessness of celecoxib, a selective COX-2
inhibitor [4, 5]. It is a poor activator when compared to
ASA or to diclofenac. However, results observed with keto-
profen are contradictory: it is one of the strongest COX-
1 inhibitors [15, 16]( T a b l e1)b u tw a sap o o ra c t i v a t o ri n
BATandMATeventestedathigherconcentrationsthanASA
or diclofenac. This suggests that inhibition of COX-1 is not
enough to activate leukocytes. It remains to determine the
signiﬁcation of cellular responses to NSAIDs and the cor-
relation with the disease evolution. Though nonimmune,
NSAID hypersensitivity in most patients is acquired and
occurs around the age of forty years (Table 2). In a follow up
for 4 years, a third of the patients recovered [3]. Intolerance
to NSAID might precede by years the onset of CIU [39].
Twenty out of 60 (33%) patients reported in addition to
NSAID APAP hypersensitivity, but, when tested with APAP,
skin tests, BAT, and MAT were negative. The mechanism by
which APAP aﬀects fever and pain is still debated. It remains
a weak COX inhibitor, but it is more potent in inhibiting
COX-2 than COX-1, like selective COX-2 inhibitors [17].
One team published contradictory results about the
sensitivity of the BAT, it reported that diclofenac induces
basophil degranulation without increasing CD63 expression
insensitivepatients[25].However,thehighestconcentration
of diclofenac they used was 10μg/mL, which is 8 times lower
than the concentration used in the other published works
[22, 23, 26]. We observed, in agreement with published
works for basophils and also for monocytes, that they
were better activated by increasing the concentration of
NSAIDs. But the too high concentrations (≥5mg/mL for
ASA, ≥1.25mg/mL for diclofenac) were toxic or activated
nonspeciﬁcally the basophils of the controls [36, 37, 40].
CD203c upregulation, compared to CD63, poorly
detected basophil activation by NSAIDs, but there is a
controversyaboutCD203cupregulationbyNSAIDs[37,38].8 Journal of Allergy
Discrepancies about the sensitivity of CD203c compared to
that of CD63 might have diﬀerent explanations [31, 34, 41].
Insummary,inpatientssuﬀeringfromNSAIDhypersen-
sitivity restricted to cutaneous reaction, in vitro activation
of basophils or monocytes by NSAIDs was similar to that
of control subjects. In contrast, a group of patients who had
had early and quite severe reactions (grade II) had with ASA
signiﬁcantly stronger activation of basophils and monocytes.
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